Syngen BiotechLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Syngen BiotechLtd ha un patrimonio netto totale di NT$2.2B e un debito totale di NT$237.7M, che porta il suo rapporto debito/patrimonio netto a 10.9%. Le sue attività totali e le sue passività totali sono rispettivamente NT$3.0B e NT$818.7M. L'EBIT di Syngen BiotechLtd è NT$305.1M rendendo il suo rapporto di copertura degli interessi 40.9. Ha liquidità e investimenti a breve termine pari a NT$228.3M.

Informazioni chiave

10.9%

Rapporto debito/patrimonio netto

NT$237.73m

Debito

Indice di copertura degli interessi	40.9x
Contanti	NT$228.31m
Patrimonio netto	NT$2.18b
Totale passività	NT$818.68m
Totale attività	NT$3.00b

Aggiornamenti recenti sulla salute finanziaria

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Mar 25

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Recent updates

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 14

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Nov 25

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NT$1.0B ) di 8279 superano le sue passività a breve termine ( NT$471.7M ).

Passività a lungo termine: Le attività a breve termine di 8279 ( NT$1.0B ) superano le sue passività a lungo termine ( NT$346.9M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 0.4% ) di 8279 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 8279 si è ridotto da 17.5% a 10.9% negli ultimi 5 anni.

Copertura del debito: Il debito di 8279 è ben coperto dal flusso di cassa operativo ( 143.8% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 8279 sono ben coperti dall'EBIT ( 40.9 x copertura).

Syngen BiotechLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.67 (vs NT$2.59 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$1.83 (vs NT$2.76 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of NT$5.00 per share

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations

Syngen Biotech Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$2.59 (vs NT$3.37 in 3Q 2022)

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$5.00 per share at 2.9% yield

Full year 2022 earnings released: EPS: NT$11.85 (vs NT$8.77 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: NT$3.37 (vs NT$2.54 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$4.00 per share

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS NT$2.54 (vs NT$2.20 in 3Q 2020)

Upcoming dividend of NT$3.50 per share

Second quarter 2021 earnings released: EPS NT$2.25 (vs NT$2.75 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.53 (vs NT$1.48 in 1Q 2020)

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS NT$7.95 (vs NT$7.86 in FY 2019)

Syngen Biotech Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day high: NT$113

Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

New 90-day low: NT$107

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Third quarter earnings released

New 90-day low: NT$107

First half earnings released

New 90-day high - NT$130

First half earnings released

New 90-day high - NT$120

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane